Similar articles

• Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma.

  Hosokawa Y, Kishino T, Ono T, Oyama N, Hayashi K, Momose H. Hosokawa Y, et al. Int J Urol. 2004 Oct;11(10):906-8. doi: 10.1111/j.1442-2042.2004.00914.x. Int J Urol. 2004. PMID: 15479299
• Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience.

  Marx G, Taylor J, Goldstein D. Marx G, et al. Intern Med J. 2005 Jan;35(1):34-8. doi: 10.1111/j.1445-5994.2004.00749.x. Intern Med J. 2005. PMID: 15667466
• [Immunotherapeutic treatment for metastatic renal carcinoma].

  Hidalgo Pardo F, Gutiérrez Sanz-Gadea C, Rebassa Llull MJ, García Bueno JM, Mus Malleu A, Losada González GP, Ozonas Moragues M. Hidalgo Pardo F, et al. Actas Urol Esp. 1998 Jan;22(1):29-33. Actas Urol Esp. 1998. PMID: 9542189 Spanish.
• Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.

  Parton M, Gore M, Eisen T. Parton M, et al. J Clin Oncol. 2006 Dec 10;24(35):5584-92. doi: 10.1200/JCO.2006.08.1638. J Clin Oncol. 2006. PMID: 17158544 Review.
• Chemotherapy for advanced renal-cell carcinoma: 1983-1993.

  Yagoda A, Abi-Rached B, Petrylak D. Yagoda A, et al. Semin Oncol. 1995 Feb;22(1):42-60. Semin Oncol. 1995. PMID: 7855619 Review. No abstract available.